Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F11%3A7062" target="_blank" >RIV/00064203:_____/11:7062 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/11:7062

Výsledek na webu

<a href="http://www.ncbi.nlm.nih.gov/pubmed/21658646" target="_blank" >http://www.ncbi.nlm.nih.gov/pubmed/21658646</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report

Popis výsledku v původním jazyce

Chronic pulmonary infection with P aeruginosa develops in most patients with cystic fibrosis (CF); by adulthood 80% of patients are infected and chronic P. aeruginosa infection is the primary cause of increased morbidity and mortality in CF. Chronic infection is preceded by an intermittent stage of infection. The initial stage is characteristically followed by the gradual emergence of mucoid variants of the colonizing strains and a rise in anti-Pseudomonas antibodies. In addition to optimizing existingtherapeutic strategies, effective new agents need to be identified. Studies in patients with CF are particularly challenging: the progressive nature of the disease and the wide variation in severity influence considerably the outcome of drug testing. A validated, universally accepted, and clinically useful classification of patients infected with P aeruginosa, particularly those chronically infected, is needed that can be used as both a criterion for patient selection for clinical trials

Název v anglickém jazyce

Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report

Popis výsledku anglicky

Chronic pulmonary infection with P aeruginosa develops in most patients with cystic fibrosis (CF); by adulthood 80% of patients are infected and chronic P. aeruginosa infection is the primary cause of increased morbidity and mortality in CF. Chronic infection is preceded by an intermittent stage of infection. The initial stage is characteristically followed by the gradual emergence of mucoid variants of the colonizing strains and a rise in anti-Pseudomonas antibodies. In addition to optimizing existingtherapeutic strategies, effective new agents need to be identified. Studies in patients with CF are particularly challenging: the progressive nature of the disease and the wide variation in severity influence considerably the outcome of drug testing. A validated, universally accepted, and clinically useful classification of patients infected with P aeruginosa, particularly those chronically infected, is needed that can be used as both a criterion for patient selection for clinical trials

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FC - Pneumologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Cystic Fibrosis

ISSN

1569-1993

e-ISSN

—

Svazek periodika

10

Číslo periodika v rámci svazku

—

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

4

Strana od-do

"S75"-"S78"

Kód UT WoS článku

000292068000011

EID výsledku v databázi Scopus

—